TABLE 1.

circRNAs as biomarkers in liquid biopsy for the diagnosis of NSCLC.

circRNA	Expression level	Intersection molecules and/or pathway	Effect	Sample	AUC	References
circ_0008928	Up	miR-488/HK2 axis	Regulates cisplatin sensitivity, tumor progression, and glycolysis metabolism.	Serum exosomes		Shi et al., 2021
circ_PIP5K1A	Up	miR-101/ABCC1 axis	Regulates the progression of NSCLC and cisplatin sensitivity.	Serum and serum exosomes		Shao et al., 2021
circCDYL	Down	miR-185-5p/TNRC6A axis	Inhibited cell viability, proliferation, and induced apoptosis.	Plasma		Bian et al., 2021
hsa_circ_0014235	Up	miR-520a-5p/CDK4 axis	Promotes cisplatin chemoresistance and deteriorates the development of NSCLC.	Serum exosomes		Xu et al., 2020
has_circ_0060937	Up	–	Closely associated with bone metastasis in NSCLC.	Serum		Zhang J. et al., 2020
hsa_circ_0046264	Up	–	Notably associated with the patient’s age, tumor size, TNM stage, and lymph node metastasis.	Serum	0.915	Liu et al., 2020
circ-MEMO1	Up	miR-101-3p/KRAS axis	Promotes the progression and aerobic glycolysis of NSCLC.	Serum exosomes	0.760	Ding et al., 2020
circARHGAP10	Up	miR-638/FAM83F axis	Promotes proliferation, migration, invasion, and glycolysis.	Serum exosomes	–	Fang et al., 2020
circPVT1	Up	–	Associated with chemotherapy resistance.	Serum	–	Lu et al., 2020
hsa_circ_0002130	Up	miR-498/GLUT1/HK2/LDHA axis	Facilitates osimertinib resistance.	Serum exosomes	–	Ma et al., 2020
the panel of circ_0047921, circ_0056285, and circ_0007761	Up, Up, Down	–	Distinguishing early-stage NSCLC cases from healthy controls, chronic obstructive pulmonary disease controls, or tuberculosis controls.	Serum exosomes	0.919	Xian et al., 2020
circSATB2	Up	miR-326/FSCN1 axis	Promotes the proliferation, migration, and invasion of NSCLC cells.	Serum exosomes	–	Zhang N. et al., 2020
hsa_circRNA_012515	Up	–	May be a mechanism leading to gefitinib resistance in NSCLC patients.	Peripheral blood	–	Fu et al., 2020
hsa_circ_0134501 combined with hsa_circ_0109320	Down	–	Biomarker candidates for predicting the therapeutic effect of gefitinib in NSCLC.	Plasma	0.79	Liu Y.-T. et al., 2019
circ FECR1	Up	miR584-3p/ROCK1 axis	Predicts survival outcomes and predicts the response to chemotherapies.	Serum exosomes	–	Li et al., 2019
F-circEA	Exist	–	Could be a novel “liquid biopsy” biomarker to monitor the EML4-ALK fusion gene in NSCLC.	Plasma	–	Tan et al., 2018
hsa_circ_0102533	Up	–	Possesses an oncogenic property in the carcinogenesis.	Whole blood	0.744	Zhou et al., 2018
circFARSA	Up	miR-330-5p/FASN or miR-326/FASN axis	Promotes cell migration and invasion.	Plasma	0.71	Hang et al., 2018
hsa_circ_0013958	Up	miR-134/CCND1 axis	Promotes cell proliferation and invasion and inhibits cell apoptosis.	Plasma	0.794	Zhu et al., 2017

TNM, tumor-node-metastasis; AUC, area under the ROC curve (AUC).